Evicenter
MarkdownMedical informationP&T meetings
Vonaprument (ANX007)

Geographic atrophy secondary to age-related macular degeneration

Launch
Not announced
Last updated
167 sources

Economic information and modeling report

Modeling overview

8 evidence topics · 8 sources

Summary: absence of vonaprument economic evaluations and comparator cost-effectiveness evidence

No cost-effectiveness analysis, budget impact model, health technology assessment, or price of vonaprument (ANX007) was identified. ARCHER II, the phase 3 trial of monthly vonaprument 5.0 mg per eye versus sham in 659 participants, had a Data Monitoring Committee assessment of its Month 15 primary endpoint scheduled for the fourth quarter of 2026, so no product-specific efficacy input for a model was available. The manufacturer states that there is no assurance a product will be considered “cost-effective by third-party payors”. The comparator evidence consists of analyses of the two complement inhibitors approved in the United States, pegcetacoplan and avacincaptad pegol.

Two U.S. cost analyses based on 2022 Medicare reimbursement, estimated 2-year treatment costs of $70,000 (every month) and $34,600 (every other month) for pegcetacoplan, with modeled costs per QALY gained of $706,000 and $397,000, and 2-year costs of $67,400 (every month) and $40,600 (every other month) for avacincaptad pegol. For extrafoveal GA, the cost per mm2 of retinal pigment epithelium saved was higher with avacincaptad pegol than with pegcetacoplan for both dosing regimens ($119,000 vs $54,000 every month; $57,100 vs $31,400 every other month). A U.S. cost-utility model with authors from Apellis Pharmaceuticals, which included the costs and utility loss of informal caregiving, reported $77,735 per QALY gained over a lifetime horizon, and $55,806 per QALY gained for lesions at least 250 μm from the foveal center.

The Australian Pharmaceutical Benefits Advisory Committee (PBAC) assessed submissions for pegcetacoplan (November 2025) and avacincaptad pegol (March 2026). Each submission was a cost-utility analysis versus best supportive care with a 20-year time horizon; the pegcetacoplan model defined health states by ETDRS letter bands, and the avacincaptad pegol model by GA lesion size. For both products the PBAC stated that a price reduction would be required to achieve cost-effectiveness, and considered an ICER in the order of $55,000 to < $75,000 (pegcetacoplan) and $45,000 to < $55,000 (avacincaptad pegol) per QALY gained acceptable. For pegcetacoplan, the PBAC considered it reasonable to accept the financial estimates as the basis of a risk sharing arrangement. Should pegcetacoplan proceed to listing, the PBAC advised a cost-minimisation approach so that avacincaptad pegol was no more costly than pegcetacoplan. The NICE appraisal of pegcetacoplan was suspended after information the company provided in February 2025, which stated that it had not received MHRA marketing authorisation for the indication, and has since been discontinued.

Australian PBAC assessment of avacincaptad pegol: model structure, ICER, and cost-minimisation with pegcetacoplan